4D Pharma (LON:DDDD) said an early stage clinical study of its drug candidate for irritable bowel syndrome (IBS) seems to be well tolerated by patients receiving it.
Interim data from the phase I trial of Blautix, conducted in both healthy volunteers and people with IBS, also “appears to support the pharmacological hypothesis” of the putative treatment, 4D said.
Chief scientific officer Alex Stevenson added: “We look forward to reporting further results from the trial shortly, when dosing in IBS patients is completed.
“We believe our approach of identifying and developing novel live biotherapeutic products from healthy human samples gives us an advantage in terms of safety, and also allows us to rapidly develop drug candidates for diseases where current treatments may be associated with severe side effects."
Phase I studies are designed to test elements such as safety, dosing and how well tolerated the drug by the human body rather than efficacy.
